New drug profile: Maraviroc: it's different, it's strong, and it's almost here.(Drug overview)
Publication Date: 01-JUN-07
Publication Title: HIV Treatment: ALERTS!
Format: Online
Company: Pfizer Inc.~Product development

Read this article now
Try Goliath Business News - FREE!

You can view this article PLUS...

  • Over 5 million business articles
  • Hundreds of the most trusted magazines, newswires, and journals (see list)
  • Premium business information that is timely and relevant
  • Unlimited Access

Now for a Limited Time, try Goliath Business News
Free for 7 Days!

Tell Me More   Terms and Conditions

Purchase this article for $4.95

Description

What is it?

Maraviroc (or Celsentri) is an HIV medication, the first of its kind. Maraviroc doesn't block HIV directly; instead, maraviroc binds to a human protein known as CCR5. This is one of the proteins HIV uses to enter human T cells. By binding to CCR5, maraviroc keeps HIV from infecting T cells.

Who's it for?

Maraviroc, in combination with other HIV meds, is indicated for treatment-experienced adults infected with CCR5-tropic (attracted to something specified) HIV.

What does that mean?

In order for HIV to infect a T cell, the virus must first...



More articles from HIV Treatment: ALERTS!
Fuzeon update.(Brief article), June 01, 2007

Looking for additional articles?
Click here to search our database of over 3 million articles.